Hi all
pretty new to all this. I have pumped some into Deltex - looks like a strong product with good growth. Could be a steady gainer.
Does anyone else have this, and anyone have some research on it? Someone with more experience than me!
thanks in advance.
Grajul

Institution? Surely that's just MAN Financial who do spread bets. That's a load of spread betters closing their positions. That's nothing to worry about.

Me, I'm patient. The patient dog eats the fattest bone.

Hi Arf Dysg,

Could be as you say but Man Financial have been connected to Deltex for some time, and also deal in online futures, options, 'equities', forex, CFD's, free research and quotes.
.

Man Financial Limited first mentioned on 10/01/06 when they declared a holding of 2,360,000 putting them over the notifiable threshold.
They had 3,260,000 21/02/06 reduced to 3,135,000 on 22/02/06 so they must have bought another 900,000 sometime between the 2 dates.
The latest sale of 635,000 as stated puts them below the notifiable threshold, but still leaves them with a reasonable size holding.
So they look to have been in Deltex (with a notifiable holding) from 10/01/06.
If they held a lesser amount before that we have no way of knowing.

But like you patient, and not worried.

RNS out.

This placing will represent approximately 8.97 per cent. of the entire
issued share capital of the Company immediately following Admission.

'Deltex Medical has reached a key stage in its development where it is
experiencing both sustained and sustainable growth in all of its key markets.
Furthermore the Company's potential for future growth has been enhanced
significantly by the recent announcement of reimbursement coverage in the USA.
This investment in the expansion of our manufacturing capacity will allow us to
meet the rising demand for our products.'

Placings are sometimes for good reasons, sometimes bad. I will go with this placing being positive for the sole reason I believe some orders are in the pipeline and the extra funds are needed to speed up the manufacturing progress.

All IMHO of course.

THE COUNT--->ALL

Ooops, I wrongly posted this earlier on the traders thread thinking it was this one.

Post as follows....

THE COUNT--->ALL

The placing price is slightly disappointing, but then again, who llikes placings for any reason? I understand the company were hoping to do this at around the 25p mark but institutions originally wanted to do this at 20p and the company turned it down.

I wasn't aware of this until very recently, but the company, by this month, were running close to their capacity to produce probes. Obviously this signifies growth and it is a fact that all their territories have continued to grow. Given the setting of our market, you cannot fail to deliver on any orders as otherwise, it would be lethal to the company itself.

The bulk of the monies is to be used to fund a large expansion in the production capacity....I understand this to be up to a capacity of 20,000 probes per month from a present cpacity of 6,000 - 7,000 probes per month.

The company cannot raise any more money as this is their present limit without holding an EGM. I know its not a pleasant thing to do for existing shareholders, but it really was due to prohibitive costs that they didn't bring everybody in on the placing. The placing was done very quickly.

It's also the case that many investors regard all placings to be an evil force from the dark side. It is a necessary and important function of having a stockmarket ilsting and it is being done predominantly to fund the necessary expansion in our capacity.

The signs are all there...they are running close to capacity now and are expecting to reach their limit shortly....likely in the second half of the year. We sold about 39,000 probes throughout the whole of last year. If they reach their capacity of say 6,500 probes per month, that would annualise the probe sales at about 78,000 units. Now with the increased capacity, we will have the potential for about 240,000 units pa.

I don't like this as much as any of you, but it is necessary. For now I am biting the bullet.

Regards.

THE COUNT!

The Count,

Thanks re the extra detail.

Looks like the PI's liked it. On a bad day for the market Deltex are up.

Now will be nice to see, either new institutions buying, or/and existing ones increasing holdings.

Greek.

All, been in and out of DEMG three times, twice at frustrating losses triggered by stops and once re-couping them back with a well timed buy low, sell high.
Just wondered whether DEMG is now about to realise the potential but also thoughts on the competition Lidco? They reported strong sales this week but also received a patent in USA.

I have posted their RNS's below for your comments compared to DEMG?
I currently have no investment in either but DEMG has been on my watchlist for what seems to be forever.

LiDCO Group Plc
('the Company')

AGM Trading Update
Revenue Growth - Driven by Monitor Placements

LiDCO, the UK based, AIM-quoted cardiovascular monitoring company, will today
hold its Annual General Meeting at 11am. At the meeting Dr. Terry O'Brien,
Chief Executive of LiDCO, will provide the following update on trading:

"The Company stated in its preliminary results in April that it had already
seen a healthy increase in revenues. I am pleased to be able to report
encouraging results for the first four months of trading to the 31st of May
with sales up 61% over the equivalent period last year. Increased revenues have
been achieved in all territories - with particularly marked growth seen in
Europe. Sales have been driven by a shortening of the monitor sales cycle
during the period. The installed base is now standing at 1098 units
representing an increase of 189, 21%, over the last 12 months. Margins
(excluding our leasing arrangements) have been maintained and administration
expenses continue to be well controlled and within managements' budgets.

The Directors of the Company believe that the competitive activity remains
strong and that LiDCO remains on track to achieving expectations."

Notes for Editors

About LiDCO Group Plc
LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of
minimally invasive, computer-based hemodynamic monitoring equipment and
disposables used primarily for the management of critical care and
cardiovascular risk hospital patients. Use of LiDCO's technology has been shown
to significantly reduce the complications (particularly infections) and costs
associated with major surgery. The technology was invented in the Department of
Applied Physiology based at St Thomas' Hospital, London. For more information
please see
www.lidco.com
.

The Company's manufacturing facility is in Hoxton, London and its current
products are:

* LiDCOplus and PulseCO monitors: computer-based platforms for displaying a
range of real-time, continuous hemodynamic parameters including cardiac output,
oxygen delivery and fluid volume;

* LiDCO disposables: used in conjunction with the LiDCOplus Monitor to
accurately determine cardiac output in a minimally-invasive manner.

* LiDCOview - software product for use on a PC: designed to aide clinical
audit, teaching and research activities.

* LiDCOlive - software product in development for the remote display of
hemodynamic monitoring parameters derived through use of the LiDCOplus monitor.

Distribution Network:

The Company has now achieved registration of its products in 14 markets in
Europe, the USA, Brazil, South Korea and Japan. It sells direct in the UK and
USA, and elsewhere through a worldwide network of specialty critical care
distributors.

LiDCO Group Plc

('the Company')

Grant in the US of a Patent for Setting and Adjusting of a Cardiac
Biventricular Pacemaker

Supports Interventional Cardiology Opportunity

LiDCO, the UK based, AIM-quoted cardiovascular monitoring company, today
announces that it has received confirmation of the approval of its US Patent
application for a new method and apparatus for optimally adjusting a
biventricular pacemaker - used for the treatment of congestive heart failure
(CHF). The method involves the measurement of changes in certain hemodynamic
parameters (arterial pulse pressure and stroke volume) that have been shown to
reflect improvements in the heart's pumping action (ventricular performance).
Using the LiDCOplus Monitor these parameters are measured minimally invasively
and beat-to-beat.

Dr Terry O'Brien (Chief Executive of LiDCO) stated: "The use of our technology
today is predominantly for the treatment of intensive care and anesthesia
patients. However, we have always thought that the interest in using our
products within interventional cardiology would grow as the biventricular
pacemaker market developed. Accordingly, a number of influential university
hospitals are field trialing the use of our technology with a view to improving
the response of patients being treated for CHF with implantable biventricular
pacemakers. Although this is still somewhat early days, the grant of additional
intellectual property in this arena means that if the results of these trials
prove positive, we should have a strong and protectable market position."

Background to CHF, the patent and its usefulness in CRT/biventricular pacing:

Progressive congestive heart failure (CHF), is a growing problem among men and
women age 50-80 years. The condition affects 2-4 million people in the United
States and nearly 15 million people worldwide. The economic cost of heart
failure is estimated at $40 billion per year. Heart failure is a clinical
syndrome caused by a reduction in the heart's ability to pump blood around the
body. The heart's main chambers (the ventricles) should pump simultaneously and
in synchrony with the heart's upper chambers (the atria). If the wave of
contraction lacks synchrony the heart becomes less efficient as a pump and
starts to deteriorate. The problem underlying heart failure is one of delay in
the electrical activation of the left ventricle. This causes inefficient
pumping of blood to the body. The patient experiences a range of symptoms
including shortness of breath, swelling in the ankles or legs, weight gain, and
fatigue (`heart failure').

Recent pharmaceutical-based therapeutic advances have resulted in decreased
mortality rates in patients with CHF. However, despite these advances the
overall long-term prognosis and quality of life are still limited in patients
with moderate to severe heart failure. Therefore, device-based therapeutic
approaches are also warranted. Cardiac resynchronization therapy (CRT), or
biventricular pacing, aims to restore synchronous cardiac contraction by
delivering electrical impulses to three of the four chambers of the heart - the
right atrium and both ventricles. The result is that both ventricles beat in
synchrony, thus improving the pumping action of the heart and reducing the
symptoms of heart failure. CRT devices are available for sale for the treatment
of heart failure and are manufactured and sold by some of the biggest
cardiovascular corporations including Medtronic, Guidant and St. Jude Medical.
A number of studies have indicated that implantation of these devices improves
the clinical symptoms of people with heart failure. The devices cost thousands
of pounds each and require a surgical procedure/operation to implant both the
device and the wires.

In order to reduce the symptoms of heart failure, CRT devices can adjust/reset
the electronic conduction delay times from the atrium to the ventricles, thus
reducing the lack of cardiac synchrony. In a significant number of cases this
approach does not improve the clinical symptoms of heart failure. This can be
because the patient's heart will not respond to this approach, but also because
the device has not been optimally set up and/or adjusted to improve the
patient's ventricular performance. LiDCO's patent outlines how the LiDCOplus
Monitor can be used in conjunction with the outlined method in order to improve
patient screening for biventricular pacing suitability, to improve the
electrical lead placement, and to optimize pacemaker settings in terms of
choosing the appropriate heart rate and various chamber delays.

Hi Andysmith,

Hope this will help re competition from LiDCO.

This article was posted in Acuity Care Technology, June/July issue 2007
Today, the device choices are many and the technological approaches diverse for noninvasive hemodynamic monitoring of the critically ill patient.
By Judy Hostert-Harvey.

The article compares several companies products and is well worth a read.
Due to it's length those interested see link.
http://new.reillycomm.com/acuity/special-report2.php?id=394

I have been following and holding shares in Deltex for several years and strongly believe after following many clinical trails re the CardioQ and it's competitors that Deltex have the edge in technology and a lead in proven trial numbers.

But as a holder, I would say that wouldn't I.

Back in November 2003 I invested in Deltex Medical plc, form then until about six weeks ago I have held onto the stock and sat on my hands, waiting for the S.P. to move into profits. At long last I am in profit to the tune of 26% for shareclubuk.co.uk. The key to all of this is the company product CardioQTM and the NHS. The product is first class and at long last the NHS is opening its eyes to the saving that CardioQTM makes for them. Also the new business wins that the company has made in the US market place has help matters along, so much so that the company has made a placing to fund the extra business, could we have another Tanfield on our hands. My view now is that there will be a lot more profits to come.

And another successful trial result.

International endorsement of CardioQTM for critically ill children.

Still patient. Sp trickling up nicely of late. Lets hope the usual slide down that occures, if no follow up contracts does not happen this time.

Can't be too long now surely.

This is not directly linked in any way with Deltex, but in my opinion it cant do any harm and may well do them (Deltex) some good.(see below re Sir Ara Darzi)

Gordon Brown our new PM, has announced that he wants experts from industry, the NHS and other organizations to assist and advise the Cabinet.
Already he has appointed 5 experts in their own field, Sir Digby Jones (business), Shriti Vadera (investment banker), Admiral Sir Alan West (defense), Lord Stevens (retired Police Chief), and Sir Ara Darzi (The surgeon drafted into the Brown government to help boost the NHS is one of Britain's leading experts in keyhole surgery). Sir Darzi is charged with improving patient care.

OK as yet we don't know if it's just another labour spin job, but although in no way a fan of Gordon Brown, I do feel he will try to make a quick dynamic change to several important areas such as the NHS. Whether he succeeds is another matter.

The appointment of Sir Ar Darzi, is a contentious one as he has already shown that he is not a yes man and is quite prepared to speak his mind.

He spoke strongly against the closure of some NHS hospitals, upsetting several ministers. He is honorary consultant surgeon at St Mary's Hospital and The Royal Marsden Hospital in London.
He is a pioneer of minimally invasive surgery and has been conducting a review of London health care.

Now if Mr Brown allows those that have done the job and know from the inside what is required to get on with it, who knows the 60 plus clinical trial results on the CardioQ might just be taken at the value that is obvious to everyone than can read, and add up cost versa savings, (I suppose it does not include our illustrious NHS managers and the now defunct Health Secretary Patricia the NHS has never had it so good useless Hewitt) we might just start spending money wisely.

Perhaps I am being optimistic re these appointments, but I do strongly feel that if they don't get to grips quickly with the NHS, the public funded systems days will be numbered.
Whichever way it goes, the NHS spending money more wisely, or the private/partially funded health service it can only be good for the likes of Deltex.

In the short term I still think that the near or/and mid future of Deltex is not in this country. Long term perhaps.

A novel idea really, employing people who have experience/success in the job that they will be advising on. Not rocket science is it.

Well greekman, the NHS will have to spend their money even more wisely now we find that one of the last acts as chancellor our new PM reduced NHS funding by 2billion, from 6.2b to 4.2b. Now that's a good start for sorting the NHS out--NOT. In England we cannot receive Rituximab (for Rheumatoid Arthritis) on the NHS, but guess what - in Scotland they can.
2517

Hi George,

Yes, I had noticed the reduction in funding, but if I remember correctly, the amount put in for the sole intention of reducing the debt was almost equal with the drop in funding. The debt of the NHS trusts has according to the Government been eradicated. I think the figures as usual have been fiddled, and no matter what the government tell us, huge amounts of cash have been saved due to vast reductions in treatments, operations. In our area, you now go on an unofficial waiting list to get on the official waiting list.
But I do think as you say, finance accountability, spending more wisely will have to sustain the finance reduction.

Lets hope common sense comes more into spending decisions, IE spend to save.

Problem is does common sense and Government decisions don't go together.

As to the Scottish patient, receiving a better deal than the rest of the UK, I can't agree with you more. As we all know this unequalness is there in many areas, not just health.

Wont go further down this road as I don't want to go too far from the threads theme.

I think, I will buy a caravan, move to Scotland, change my name to Jock McTavish, wear a kilt and have haggis for breakfast. (I do love haggis).

So wishing you, "Och I The New". (No I can't spell and my spell checker gave up, and I don't know what it means).

"Och Aye" - Oh Yes
"The Noo" - Now

How's that? Spell checkers be damned.

Thanks Arf,

Knew someone would put me right. Clever ***.
At least I am better at picking shares (not by much) than I am at spelling.

Charles Stanley reiterated its "Buy" stance for Deltex Medical (DEMG), citing the potential for revenue growth of 40% for the three years to 2009 and the company's plausible attraction as a takeover target. However, its shares shed 0.75p to 27.5p.

Still out of favor with the market, but I think the Charles Stanley projection is on the conservative side.

Yet another report on the benefits of CardioQ.
2517

Yes as you say yet another, although you can't really have too many, but how many more are required before the NHS mis-managers get their very dim fingers out and buy the b****y thing. They remind me of those three monkeys, hear nowt, say nowt, see nowt,( yes I know it was a bit of poetic license).

Still think the first real big NHS contract will come this year, which will start the ball rolling.

There has to be plenty in the pipeline, due to the extra capacity, Deltex are gearing up to.

greekman -------- With DEMG gearing up to cope with demand ahead of that demand, I believe it shows the forward thinking management are in front of the curve, and that DEMG will be ready for the increase in capacity as it materialises, as it surely will.
2517